User login

TPP Meets 'May 10' Standard On Biologics; Other IP Provisions Fall Short

October 8, 2015 at 9:34 PM
ATLANTA -- The biologics compromise included in the Trans-Pacific Partnership (TPP) deal announced this week appears to be consistent with the so-called May 10 agreement as interpreted by Rep. Sander Levin (D-MI), one of its principal architects. But other aspects of TPP's rules governing intellectual property (IP) protection for medicines have been previously blasted by Levin as going against the May 10 deal. The final deal on biologics would require TPP countries to comply with either of two options, the...

Not a subscriber? You can request 30 days free access to exclusive, behind-the-scenes reporting on trade policy in the Biden era.